In early September, the Marker X team collaborated with the Management Bureau of Central Taiwan Science Park for the first time to host a seminar, which houses many professional firms. The seminar was aimed at industry professionals and featured Mr. Zhengjie Gong, Business Manager and Sales Trainer at Marker X, sharing the latest AI-based early cancer screening technology. He discussed how this technology can effectively help users detect cancer risks early, enabling them to undergo further testing and effectively halt the progression of tumors within the body. Despite being a Friday evening, many attendees overcame traffic congestion to participate in the lively discussion before the weekend.
Application of Early Cancer Screening with Cancer Proteomics
The uniqueness of this technology lies in its ability to rapidly and accurately detect cancer risks by analyzing patients’ blood samples. Traditional cancer screening methods typically require expensive and complex imaging tests or tissue biopsies, which are time-consuming and may cause discomfort to the subjects. In contrast, the Marker X early cancer screening technology requires only 3ml of blood sample and provides highly sensitive screening results. This means that users no longer need to endure painful examination processes and can detect cancer risks earlier, thereby increasing the success rate of treatment.
During the Q&A session, many meaningful questions were raised, with one of the most frequently asked being: ‘What is the difference between Marker X’s AI early cancer screening and conventional genetic testing?’ The key difference lies in that genetic testing can determine an individual’s inherent risk of developing specific cancers (genomic composition), while protein testing can dynamically display the current state of the body (lifestyle). Marker X’s technology can achieve an accuracy rate of over 90% in the detection of four types of cancer (breast, lung, colorectal, and esophageal cancers).
About Marker X
Our core value is to provide the best screening technology for cancer prevention, accompanying medical teams in advancing continuously, and enabling more lives to create infinite value.
Marker X’s AI-based early cancer screening technology uses advanced instruments to analyze the protein composition in the blood for cancer risks. With our proprietary ‘multi-index algorithm,’ we lead the global market in effectively assisting the public in early detection and treatment of various types of cancer. In the future, we will expand our testing technology to screen for other chronic diseases, such as cardiovascular diseases. Additionally, we are developing companion diagnostic tests related to medication, helping doctors and patients make more comprehensive and personalized assessments before using drugs. Our partners include major teaching hospitals, diagnostic technology units, health examination centers, and research units.
During the event, discussions were also held with the Central Taiwan Science Park regarding future collaboration possibilities. For example, inviting personnel from units within the park that are at high risk of cancer to attend further briefings to understand that, in addition to existing health check-up items, there are now newer cancer screening technologies available, helping employees intercept cancer risks earlier, faster, and more painlessly. This is worth considering for all business leaders who care about the well-being of their employees.
The seminar not only showcased the potential of Marker X’s early cancer screening technology but also fostered a positive connection and interaction with technology-related companies in the central region. We look forward to our work continuing to have a positive impact on cancer prevention and early treatment, making significant contributions to public health initiatives.